AI Prostate cancer test backed by Chris Hoy is 96pc accurate

From the Daily Telegraph
A 96 PER CENT accurate prostate cancer test has been developed by scientists and backed by Olympic cycling champion Sir Chris Hoy.
The “truly game-changing” test can diagnose prostate cancer to a very high level of accuracy and identify the disease’s aggression as well as its sub-type.
Scientists at EDX Medical, the Cambridge-based digital diagnostic firm behind the initiative, said the test was more accurate than the existing protein-specific antigen (PSA) test offered by the NHS. The health service is expected to review its guidance for prostate cancer testing after it was branded “dangerously outdated” in the wake of Sir Chris’s campaign to improve access to screening following his terminal diagnosis.
EDX Medical’s test involves scientists analysing blood and urine samples in a laboratory using an AI algorithm. It then considers PSA positivity and a host of other metrics to boost its accuracy.
Sir Chris said: “I now know there is a need for better and more accurate prostate cancer screening tests and I wholeheartedly welcome this initiative.”
Prof Sir Chris Evans, the founder and chief scientific officer of EDX Medical, said: “Every indication thus far shows it will be the most accurate and sensitive screening test available and will be transformative in tackling prostate cancer in men who may have no idea if anything is wrong with them,” he said.
The firm expects the product to detect cancer 96 to 99 per cent accurately because it is based upon clinical trials using the various relevant biomarkers.
Imperial College Healthcare NHS Trust and Imperial College London are leading a trial backed by Prostate Cancer UK to assess multiple different types of prostate cancer screening tests.
The company will be seeking regulatory approval this year in both the UK and US before rolling out the product privately at the start of 2026. It will then also make an application for it to be used on the NHS, it is understood.